CJC-1295 Co
Compare available option

Research compound, not FDA-approved

CJC-1295 comes with two receipts most research peptides never have: real human trials, and a real FDA adverse-event record.

In randomized placebo-controlled trials, one injection raised growth hormone 2- to 10-fold for 6 or more days and IGF-I for up to 11, on a half-life of 5.8 to 8.1 days. The same compound appears on FDA's compounding safety-risks list with identified serious adverse events, including increased heart rate. Development stopped in 2006; no efficacy outcome was ever measured; and half the market sells a different molecule under the same name. We publish all of it, every number linked to its source.

Compare available optionBrowse the guides
  • 27fetch-verified sources; 16 peer-reviewed, 11 government or anti-doping authority
  • 14rows in the graded evidence table, species labeled on every row
  • 4of those rows are human studies; every one measured hormones, none measured outcomes
  • 0completed efficacy trials for body composition or any functional outcome

Online care, from intake to delivery

Available peptide care, made simple

Choose your plan, complete a private medical intake, and connect with a licensed provider. If prescribed, treatment ships discreetly to your door.

Available peptide care catalog product image
Compounded injectable treatmentPrepared after approval
Catalog image. Dispensed product and packaging may vary by pharmacy.

Your care plan includes

Everything you need to get started

From$242.10per month
Licensed providerMedical reviewIf prescribedTreatment includedAt no added costDiscreet shippingWhen you need itOrder support

Important: CJC-1295 is not sold through this checkout. The available option is a tesamorelin / ipamorelin blend and is labeled separately to avoid substitution confusion.

Choose your planChange or cancel future refills anytime
Due today$269.10then monthly

Encrypted checkout • provider review required • shipping included

  1. 01
    Choose your planSelect the supply and refill preference that works for you.
  2. 02
    Complete your intakeShare your health history in our private, secure flow.
  3. 03
    Provider reviewIf appropriate, your prescription is prepared and shipped.

Prescription treatment requires an online medical evaluation. A provider will determine whether treatment is medically appropriate; approval is not guaranteed.

Key facts

  • StatusResearch compound, not FDA-approved
  • Half life without dacNo published human PK for the no-DAC peptide itself; closest measured anchor: D-Ala2 substitution alone extends GRF(1-29) half-life from 4.3 to 6.7 minutes minutes (anchor values)source
  • Gh durationMean GH elevated 2- to 10-fold for 6 or more days after a single DAC dosesource
  • Igf1 durationMean IGF-I elevated 1.5- to 3-fold for 9 to 11 days; up to 28 days above baseline with repeated dosingsource
  • Albumin bindingCovalent bioconjugation of the Lys30 maleimidopropionamide linker to Cys34 of serum albumin; albumin-bound within 15 minutes in rats, persisting beyond 24 hourssource
  • Dpp4 resistanceNative GHRH is cleaved at the 2-3 bond by DPP-IV; D-Ala2 blocks this cleavage, and the tetrasubstitution plus albumin shielding confer measured in vitro DPP-IV stabilitysource
  • Trough effectOne week after a single dose: trough GH 7.5-fold higher, mean GH +46%, IGF-I +45%, pulse frequency and magnitude unalteredsource
  • ClassLong-acting GHRH analog (tetrasubstituted GRF 1-29 + DAC)Regulatory recordsource
  • Half-life (with DAC)5.8 to 8.1 days daysHuman PKsource
  • GH response2- to 10-fold for 6 or more days after one doseHuman RCTsource
  • IGF-I response1.5- to 3-fold for 9 to 11 days after one doseHuman RCTsource
  • PulsatilityPreserved; trough GH raised 7.5-fold at 1 weekHuman trialsource
  • FDA adverse eventsSerious AE reports: increased heart rate, systemic vasodilatory reactionRegulatory recordsource
  • RouteSubcutaneous injection in all human studiesHuman RCTsource
  • DevelopmentPhase 2 (HIV visceral obesity) TERMINATED 2006; no active trialsRegistry recordsource
  • SportWADA-prohibited at all times (S2.2.4, named)Regulatory recordsource
  • MoleculeC165H269N47O46, 3647.2 Da, 30 residues (CID 91971820)Chemical referencesource

Read the full CJC-1295 monograph

Browse by topic

Everything on CJC-1295, organized the way you research it.

Evidence26 articlesSafety15 articlesDosing12 articlesComparisons10 articlesSourcing10 articles

Free CJC-1295 tools

Practical calculators and references, each scoped and sourced.

Review-gated tools: these calculators are excluded from search and AI citation and must not be used as dosing, reconstitution, injection, or treatment instruction.

T-01Reconstitution calculatorConcentration, draw volume, U-100 syringe units, and doses per vial from vial size, water volume, and dose.T-03Study dose explorerEvery dose reported in the published literature for this compound, filterable by species and route, each row sourced.

study rows by species, from the evidence table

Fresh juniper sprigs with dusty blue berries lying on pale linen cloth in soft window light.
A wooden hourglass with pale sand on a wooden shelf against a muted sage wall.

All guides

73 in-depth, individually cited guides.

Review-gated archive: the guides below are preserved for individual medical and source review. They are excluded from search indexing and AI citation files.

Evidence 26 guides

Cjc-1295 alternatives: what the evidence actually supportsA look at real CJC-1295 alternatives, tesamorelin, sermorelin, MK-677, and DAC vs no-DAC, with the actual studies behind each option.Updated 2026-07-30Read guide →
CJC-1295 before and after: what the evidence actually showsCJC-1295 before-and-after claims mostly come from forums, not trials. Here's what IGF-1 data, GHRH biology, and dosing studies actually support.Updated 2026-07-30Read guide →
CJC-1295 first month: what actually happens, week by weekA realistic week-by-week look at a CJC-1295 first month: sleep changes, injection site reactions, what's studied vs anecdotal, and when to reassess.Updated 2026-07-30Read guide →
CJC-1295 FAQ: DAC vs no-DAC, dosing, and ipamorelinCJC-1295 questions answered plainly: DAC vs no-DAC half-life, dosing, ipamorelin pairing, side effects, and legal status, with citations to primary sources.Updated 2026-07-30Read guide →
Cjc-1295 in older adults: what the aging-GH data showsGH secretion drops steadily after age 30. Here's what studies on GHRH analogues and aging actually found, and what's real vs unproven for CJC-1295 use.Updated 2026-07-30Read guide →
CJC-1295 pros and cons: what the evidence actually showsA clear-eyed look at CJC-1295 benefits and risks, DAC vs no-DAC, the ipamorelin pairing, and where the research stops and forum lore begins.Updated 2026-07-30Read guide →
CJC-1295 rebound effect: what happens when you stopDoes GH drop below baseline after stopping CJC-1295? Here's what the pulsatility and receptor data actually show, and how the DAC form changes the picture.Updated 2026-07-30Read guide →
CJC-1295 results timeline: what changes and whenA week-by-week look at the CJC-1295 results timeline, based on GHRH/GH pharmacology data, not forum lore. What's plausible, what's not, and why.Updated 2026-07-30Read guide →
CJC-1295 reviews: what the research says vs forum claimsCJC-1295 reviews sorted by evidence quality: what peptide trials actually show, DAC vs no-DAC, ipamorelin pairing, dosing, side effects, and sourcing risk.Updated 2026-07-30Read guide →
CJC-1295 success rate: what the evidence actually showsNo study reports a CJC-1295 success rate as a percentage. Here's what the trial data on GH and IGF-1 response really shows, and how to read anecdotal claims.Updated 2026-07-30Read guide →
How long until CJC-1295 works: a realistic timelineMost users report subjective changes (sleep, recovery) in 1-3 weeks, with IGF-1 shifts in published trials taking weeks to months. Here's the real timeline.Updated 2026-07-30Read guide →
Is cjc-1295 worth it? a buyer's reality checkCJC-1295 has real receptor pharmacology but thin human outcome data. Here's what's proven, what's folklore, and what it actually costs before you buy.Updated 2026-07-30Read guide →
CJC-1295: mechanism, DAC vs no-DAC, and the evidenceCJC-1295 extends GH pulses via GHRH receptor binding. Here's what the half-life data, DAC vs no-DAC science, and ipamorelin pairing actually show.Updated 2026-07-26Read guide →
CJC-1295 and athlete drug testing: what gets caughtCJC-1295 is banned in sport under WADA's S2 peptide hormones class, detectable via biomarker passport testing, not standard urine panels.Updated 2026-07-26Read guide →
CJC-1295: what animal studies show vs human evidenceCJC-1295's core data is one 2005 human PK/PD trial (Teichman et al.) plus older GHRH animal work. No large human safety trials exist. Here's what's real.Updated 2026-07-26Read guide →
CJC-1295 before and after claims: what's real, what's notCJC-1295 before/after photos are common online but unsupported by trials. Here's what the actual GH and IGF-1 data show, and how to read the claims.Updated 2026-07-26Read guide →
CJC-1295 clinical trials: what the human data actually showsCJC-1295 has one published human trial (2006, 80 subjects). Here's what it found, what's still folklore, and how it differs from GHRP-2/ipamorelin studies.Updated 2026-07-26Read guide →
CJC-1295 human studies: what the actual data showsCJC-1295 human trials are small and short. Here's what the 2006 Teichman study and related GHRH research actually found, and what's still unproven.Updated 2026-07-26Read guide →
CJC-1295 in women: dosing, safety, and what the data showsNo clinical trials test CJC-1295 in women specifically. Here's what the GHRH and GH physiology data actually say about sex differences, dosing, and risks.Updated 2026-07-26Read guide →
CJC-1295 mechanism of action: how it triggers GH releaseCJC-1295 binds GHRH receptors on pituitary somatotrophs to pulse GH release. Learn the DAC vs no-DAC difference, half-life data, and ipamorelin pairing logic.Updated 2026-07-26Read guide →
CJC-1295 peptide results: what the evidence actually showsCJC-1295 raises GH and IGF-1 in trials, but human fat loss or muscle data barely exist. Here's what's proven, what's folklore, and what to expect.Updated 2026-07-26Read guide →
CJC-1295 results: what the research actually showsCJC-1295 raised GH and IGF-1 by 200-300%+ in a 2006 Mol Cell Endocrinol trial. Here's the real human data, the DAC vs no-DAC split, and what's still unproven.Updated 2026-07-26Read guide →
CJC-1295 stacks: ipamorelin, GHRP-6, and what evidence saysHow CJC-1295 is stacked with ipamorelin and other peptides, what the DAC vs non-DAC choice means for dosing, and where the evidence actually ends.Updated 2026-07-26Read guide →
CJC-1295 with DAC: mechanism, half-life, and evidenceCJC-1295 with DAC has a reported 5.8-8.1 day half-life vs about 30 minutes for the no-DAC version. Here's what the human study actually showed.Updated 2026-07-26Read guide →
Good alternatives for CJC-1295 peptide, compared honestlyTesamorelin is FDA-approved, sermorelin has decades of use, CJC-1295 without DAC mimics natural GHRH pulses. Here's how the real alternatives stack up.Updated 2026-07-26Read guide →
What does CJC-1295 actually do to your body?CJC-1295 is a GHRH analogue that raises GH and IGF-1 pulses. Here's what the actual pharmacology studies show, versus forum claims, with real numbers.Updated 2026-07-26Read guide →

Safety 15 guides

CJC-1295 and alcohol: what the interaction actually isNo study has tested CJC-1295 with alcohol directly. Here's what GH physiology, liver load, and sleep science say about mixing them, with real citations.Updated 2026-07-30Read guide →
CJC-1295 and antidepressants: interactions and safetyNo published trials test CJC-1295 with SSRIs, SNRIs, or other antidepressants. Here's the actual mechanism overlap, theoretical risks, and what to ask a prescriber.Updated 2026-07-30Read guide →
Cjc-1295 and birth control: does it affect hormonal contraceptionNo published data show CJC-1295 interacts with birth control. Here's what's actually known about GHRH analogues, hormonal contraceptives, and the real gaps in evidence.Updated 2026-07-30Read guide →
CJC-1295 and pregnancy: what the safety data actually saysCJC-1295 has zero human pregnancy trials. Here's what animal GHRH data, FDA pregnancy category logic, and peptide sourcing risk actually show.Updated 2026-07-30Read guide →
CJC-1295 common mistakes: dosing, storage, and pairing errorsThe most common CJC-1295 mistakes: wrong reconstitution, DAC/no-DAC mix-ups, injection timing errors, and skipping bloodwork. What research actually supports.Updated 2026-07-30Read guide →
CJC-1295 not working? 9 real reasons and fixesCJC-1295 not working for you? Reconstitution errors, timing, storage, and DAC confusion are the most common causes. Here's what the evidence actually says.Updated 2026-07-30Read guide →
CJC-1295 overdose and toxicity: what the risk actually isNo published human death or overdose threshold exists for CJC-1295. Here's what animal data, FDA warnings, and GHRH pharmacology actually say about the risk.Updated 2026-07-30Read guide →
Cjc-1295 withdrawal and stopping: what actually happensNo FDA-recognized withdrawal syndrome exists for CJC-1295. Here's what the GH axis, pituitary desensitization data, and half-life pharmacology actually say about stopping.Updated 2026-07-30Read guide →
CJC-1295 and blood work: what to test and whenIGF-1, fasting glucose, HbA1c and lipids are the core panels to run with CJC-1295. Here's what changes, what doesn't, and when to retest.Updated 2026-07-26Read guide →
CJC-1295 contraindications: who should not use itCJC-1295 is not FDA-approved for any use. Active cancer, pregnancy, and acute critical illness are the clearest contraindications. Here is the evidence.Updated 2026-07-26Read guide →
CJC-1295 drug interactions: what actually mattersNo FDA-reviewed drug interaction data exists for CJC-1295. Here's what GH-secretagogue pharmacology, insulin, corticosteroid, and thyroid drug logic actually says.Updated 2026-07-26Read guide →
CJC-1295 long term side effects: what the evidence showsNo published human trial has run CJC-1295 past 24 months. Here's what the DAC vs no-DAC studies, GHRH class data, and case reports actually say.Updated 2026-07-26Read guide →
CJC-1295 side effects: what the research and reports showInjection site reactions, flushing, and water retention are the most reported CJC-1295 side effects. Here's what's documented, what's folklore, and DAC vs no-DAC.Updated 2026-07-26Read guide →
Does CJC-1295 need to be refrigerated?Yes, once reconstituted CJC-1295 needs refrigeration and use within days to weeks. Lyophilized vials stored cold last longer. Here's the actual stability data.Updated 2026-07-26Read guide →
Is CJC-1295 safe? what the research actually showsCJC-1295 has no FDA approval and no completed long-term human safety trials. Here's what animal and short human studies actually found, and the real risks.Updated 2026-07-26Read guide →

Dosing 12 guides

CJC-1295 for beginners: what it is and how it's usedA plain-language guide to CJC-1295: DAC vs no-DAC, how it's dosed, why it's paired with ipamorelin, and what the evidence actually supports.Updated 2026-07-30Read guide →
CJC-1295 cycle length: how long to run it and whyMost protocols run CJC-1295 for 8 to 12 weeks with a break after. Here's what the peptide science and half-life data actually support.Updated 2026-07-26Read guide →
CJC-1295 DAC dosage calculator: how the math worksHow a CJC-1295 DAC dosage calculator converts mcg/kg to syringe units, why 2 mg/week is the common reference dose, and where the real evidence gaps are.Updated 2026-07-26Read guide →
CJC-1295 dosage: dose ranges, DAC vs no-DAC, and timingCJC-1295 dosage varies by DAC status: 1-2 mg/week with DAC, 100 mcg 1-3x/day without. Full protocol breakdown, evidence, and safety notes.Updated 2026-07-26Read guide →
CJC-1295 dosage calculator: how to actually work out a doseNo validated CJC-1295 dosage calculator exists for humans. Here's the math researchers actually use, the DAC vs no-DAC difference, and why mcg/kg tools mislead.Updated 2026-07-26Read guide →
CJC-1295 half life: DAC vs no-DAC explainedCJC-1295 with DAC has a half life of about 6 to 8 days; the no-DAC version (mod GRF 1-29) lasts roughly 30 minutes. Here's what that means for dosing.Updated 2026-07-26Read guide →
CJC-1295: how to inject it correctly (site, needle, timing)Step-by-step CJC-1295 injection guidance: subcutaneous technique, needle gauge, rotation sites, DAC vs no-DAC timing, and reconstitution basics.Updated 2026-07-26Read guide →
CJC-1295 injection sites: where and how it's injectedCJC-1295 is injected subcutaneously, most often in the abdomen. Site rotation, needle gauge, DAC vs no-DAC timing, and mixing with ipamorelin, explained.Updated 2026-07-26Read guide →
CJC-1295 reconstitution: the complete mixing guideStep-by-step CJC-1295 reconstitution: how much bacteriostatic water to use, storage after mixing, and the DAC vs no-DAC differences that change your math.Updated 2026-07-26Read guide →
CJC-1295 storage and shelf life: the real rulesCJC-1295 lasts 2-4 weeks refrigerated after mixing, longer if frozen unmixed. Here's what the peptide stability data actually shows, not forum guesswork.Updated 2026-07-26Read guide →
CJC-1295 timeline: what to expect week by weekWhat actually happens on a CJC-1295 timeline, week 1 through month 3+. What's studied, what's forum lore, and how DAC vs no-DAC changes the picture.Updated 2026-07-26Read guide →
How to reconstitute CJC-1295: a step-by-step protocolCJC-1295 reconstitution walked through step by step: BAC water volume, needle gauge, storage temps, and the DAC vs no-DAC handling differences.Updated 2026-07-26Read guide →

Comparisons 10 guides

CJC-1295 compounded vs brand name: what you're actually buyingThere is no FDA-approved CJC-1295 brand. Every source is a compounded or research product. Here's how to read that reality before you buy.Updated 2026-07-30Read guide →
CJC-1295 DAC or no-DAC: how the two versions differDAC adds a ~6-8 day half-life vs 30 minutes for no-DAC CJC-1295. Compare dosing, pulsatility, cost, and evidence before choosing.Updated 2026-07-26Read guide →
CJC-1295 DAC vs no-DAC: half-life, dosing, and useCJC-1295 DAC has a ~6-8 day half-life vs minutes for no-DAC. Compare dosing frequency, evidence, and the ipamorelin pairing rationale here.Updated 2026-07-26Read guide →
CJC-1295 vs GHRP-6: mechanism, evidence, and dosing differencesCJC-1295 and GHRP-6 raise GH through different receptors. Compare half-life, ghrelin/appetite effects, evidence quality, and why stacking is common but unproven.Updated 2026-07-26Read guide →
CJC-1295 vs HGH: how the two actually compareCJC-1295 raises your own GH pulses; HGH replaces GH directly. Compare mechanism, dosing, cost, and evidence gaps side by side.Updated 2026-07-26Read guide →
CJC-1295 vs ipamorelin: how the two peptides differCJC-1295 and ipamorelin work by different receptors and different half-lives. Here's the mechanism, the dosing logic, and why they're often paired.Updated 2026-07-26Read guide →
CJC-1295 vs Mod GRF 1-29: which GHRH analogue holds upCJC-1295 (with or without DAC) vs Mod GRF 1-29: half-life, dosing frequency, and what the receptor and pituitary data actually show. A real head-to-head.Updated 2026-07-26Read guide →
CJC-1295 vs sermorelin: how the two GHRH peptides differCJC-1295 has a roughly 30-min to 8-day half-life depending on DAC; sermorelin's is about 10-20 minutes. Here's what that actually changes for dosing and effects.Updated 2026-07-26Read guide →
CJC-1295 vs tesamorelin: how the two peptides differCJC-1295 and tesamorelin both stretch GHRH signaling but differ in FDA status, half-life, and evidence base. Full comparison of dosing, data, and use cases.Updated 2026-07-26Read guide →
CJC-1295 with DAC vs without DAC: the real differencesCJC-1295 with DAC has a ~8-day half-life vs about 30 minutes without DAC. Compare dosing frequency, evidence, and how each pairs with ipamorelin.Updated 2026-07-26Read guide →

Sourcing 10 guides

CJC-1295 online prescription requirements, explained honestlyCJC-1295 is not FDA-approved and legally requires a prescription from a licensed provider plus a compounding pharmacy. Here's how the real process works.Updated 2026-07-30Read guide →
CJC-1295 telehealth options: what's real and what to checkCJC-1295 telehealth routes explained: what's legit, what's not FDA-approved, and how compounding rules affect access. Read before you pay for a consult.Updated 2026-07-30Read guide →
CJC-1295 certificate of analysis explained: what to checkA CJC-1295 certificate of analysis should show purity, mass, and endotoxin data tied to a specific lot. Here's how to read one and what's missing from most.Updated 2026-07-26Read guide →
CJC-1295: compounding pharmacy vs research supplierCompounding pharmacies operate under FDA 503A/503B rules and require a prescription. Research suppliers sell "not for human use" vials with no oversight. Here's the real difference.Updated 2026-07-26Read guide →
CJC-1295 cost and pricing: what it actually runs in 2026CJC-1295 typically runs $60-$180 per vial depending on DAC vs no-DAC and dose size. Here's what drives the price and where the money actually goes.Updated 2026-07-26Read guide →
CJC-1295 legal status: is it legal to buy and use?CJC-1295 is not FDA-approved for human use. It sits in a research-chemical gray zone under 21 CFR 1300 rules. Here's what that actually means for buyers.Updated 2026-07-26Read guide →
CJC-1295 prescription requirements: what's actually legalCJC-1295 is not FDA-approved for any use. Legit access runs through 503A/503B compounding pharmacies with a prescriber's order, not forum sellers.Updated 2026-07-26Read guide →
CJC-1295 purity and testing: what the COA actually provesMost CJC-1295 COAs only confirm identity and mass, not sterility or endotoxin. Here's what >98% purity really means and how to read a real report.Updated 2026-07-26Read guide →
How to get CJC-1295: the legal, practical breakdownCJC-1295 isn't FDA-approved for any use. Here's how it's actually sourced legally, what a prescription route looks like, and what to avoid.Updated 2026-07-26Read guide →
How to verify CJC-1295 quality before you inject itNo consumer test proves CJC-1295 purity at home. Here's what COAs, mass spec, and provider vetting actually show, and what red flags mean walk away.Updated 2026-07-26Read guide →
A sage green ceramic cup beside a small stack of plain cloth-bound books on a dark oak desk.
An open notebook with blank pages beside a stack of plain paper and a small sage green ceramic cup on a dark oak desk.

Get the two-receipts brief before you believe either side

One email: the trial numbers with their limits, the FDA adverse-event text, the DAC vs no-DAC table, and the study-dose explorer, all cited to primary sources. Updates only when FDA, WADA, or a new trial changes something. No dosing advice by email. Unsubscribe anytime.

Free. No spam, unsubscribe anytime. Your address is used for this brief and nothing else.

Compare available option